AstraZeneca PLC (NASDAQ:AZN) Receives Average Rating of “Buy” from Brokerages

AstraZeneca PLC (NASDAQ:AZNGet Free Report) has been given a consensus recommendation of “Buy” by the ten research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $89.75.

Several research analysts recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th.

Get Our Latest Stock Analysis on AstraZeneca

Hedge Funds Weigh In On AstraZeneca

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA lifted its holdings in AstraZeneca by 62.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 27,329 shares of the company’s stock worth $2,131,000 after buying an additional 10,500 shares in the last quarter. Summit Trail Advisors LLC increased its position in shares of AstraZeneca by 33.5% during the second quarter. Summit Trail Advisors LLC now owns 8,597 shares of the company’s stock worth $670,000 after acquiring an additional 2,159 shares during the last quarter. Hancock Whitney Corp lifted its stake in shares of AstraZeneca by 16.8% in the second quarter. Hancock Whitney Corp now owns 10,801 shares of the company’s stock worth $842,000 after acquiring an additional 1,553 shares in the last quarter. Frank Rimerman Advisors LLC boosted its holdings in AstraZeneca by 25,673.7% in the second quarter. Frank Rimerman Advisors LLC now owns 9,794 shares of the company’s stock valued at $764,000 after purchasing an additional 9,756 shares during the last quarter. Finally, 1832 Asset Management L.P. grew its stake in AstraZeneca by 7.0% during the 2nd quarter. 1832 Asset Management L.P. now owns 65,772 shares of the company’s stock valued at $5,130,000 after purchasing an additional 4,280 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Down 0.5 %

AZN opened at $66.60 on Tuesday. The stock has a market capitalization of $206.50 billion, a price-to-earnings ratio of 31.87, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46. AstraZeneca has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The business has a 50-day moving average of $66.11 and a two-hundred day moving average of $74.46.

AstraZeneca (NASDAQ:AZNGet Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.87 earnings per share. On average, research analysts expect that AstraZeneca will post 4.11 earnings per share for the current year.

AstraZeneca Company Profile

(Get Free Report

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Further Reading

Analyst Recommendations for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.